Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis

Journal of Pediatrics

Volumn 181, Issue , 2017, Pages S45-S51.e1

  Ren, Clement L ^a   Borowitz, Drucy S ^b   Gonska, Tanja ^c   Howenstine, Michelle S ^a   Levy, Hara ^d   Massie, John ^e   Milla, Carlos ^f   Munck, Anne ^g   Southern, Kevin W ^h  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d CHILDREN'S MEMORIAL HOSPITAL   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f STANFORD UNIVERSITY   (United States)

^g HÔPITAL ROBERT DEBRÉ   (France)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

immunoreactive trypsinogen; intestinal current measurement; nasal potential difference; newborn screening; sweat chloride

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; AUSTRALIA; BACTERIUM CULTURE; CALIFORNIA; CANADA; CLINICAL FEATURE; CLINICAL PROTOCOL; CONSENSUS; CYSTIC FIBROSIS; CYSTIC FIBROSIS SCREEN POSITIVE INCONCLUSIVE DIAGNOSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR RELATED METABOLIC SYNDROME; DELPHI STUDY; DISEASE REGISTRY; EUROPE; FOLLOW UP; FRANCE; GENE SEQUENCE; GENETIC SCREENING; HUMAN; INCIDENCE; ITALY; MEDICAL SOCIETY; MEDICAL TERMINOLOGY; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); NEWBORN SCREENING; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY SYSTEM; RISK BENEFIT ANALYSIS; STUDY DESIGN; WISCONSIN; COMPLICATION; NEWBORN;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC TESTING; HUMANS; INFANT, NEWBORN; METABOLIC SYNDROME X; NEONATAL SCREENING;

EID: 85010295383     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2016.09.066     Document Type: Article

References (18)

1. 1 Farrell, P.M., Rosenstein, B.J., White, T.B., Accurso, F.J., Castellani, C., Cutting, G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 153 (2008), S4–14.
2. 2 Farrell, P.M., White, T.B., Ren, C.L., Hempstead, S.E., Accurso, F., Derichs, N., et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. J Pediatr 181S (2017), S4–15.
3. 3 Borowitz, D., Parad, R.B., Sharp, J.K., Sabadosa, K.A., Robinson, K.A., Rock, M.J., et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155:Suppl 6 (2009), S106–16.
4. 4 Mayell, S.J., Munck, A., Craig, J.V., Sermet, I., Brownlee, K.G., Schwarz, M.J., et al. A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 8 (2009), 71–78.
5. 5 Munck, A., Mayell, S.J., Winters, V., Shawcross, A., Derichs, N., Parad, R., et al. Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 14 (2015), 706–713.
6. 6 Ren, C.L., Fink, A.K., Petren, K., Borowitz, D.S., McColley, S.A., Sanders, D.B., et al. Outcomes of infants with indeterminate diagnosis detected by cystic fibrosis newborn screening. Pediatrics 135 (2015), e1386–92.
7. 7 Levy, H., Nugent, M., Schneck, K., Stachiw-Hietpas, D., Laxova, A., Lakser, O., et al. Refining the continuum of CFTR-associated disorders in the era of newborn screening. Clin Genet 89 (2016), 539–549.
8. 8 Ooi, C.Y., Castellani, C., Keenan, K., Avolio, J., Volpi, S., Boland, M., et al. Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 135 (2015), e1377–85.
9. 9 Ren, C.L., Desai, H., Platt, M., Dixon, M., Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Pediatr Pulmonol 46 (2011), 1079–1084.
10. 10 Kharrazi, M., Yang, J., Bishop, T., Lessing, S., Young, S., Graham, S., et al. Newborn screening for cystic fibrosis in California. Pediatrics 136 (2015), 1062–1072.
11. 11 Groves, T., Robinson, P., Wiley, V., Fitzgerald, D.A., Long-term outcomes of children with intermediate sweat chloride values in infancy. J Pediatr 166 (2015), 1469–1474 e1-3.
12. 12 Rock, M.J., Mischler, E.H., Farrell, P.M., Bruns, W.T., Hassemer, D.J., Laessig, R.H., Immunoreactive trypsinogen screening for cystic fibrosis: characterization of infants with a false-positive screening test. Pediatr Pulmonol 6 (1989), 42–48.
13. 13 Bombieri, C., Claustres, M., De Boeck, K., Derichs, N., Dodge, J., Girodon, E., et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 10:Suppl 2 (2011), S86–102.
14. 14 Prach, L., Koepke, R., Kharrazi, M., Keiles, S., Salinas, D.B., Reyes, M.C., et al. Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. J Mol Diagn 15 (2013), 710–722.
15. 15 Salinas, D.B., Sosnay, P.R., Azen, C., Young, S., Raraigh, K.S., Keens, T.G., et al. Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants. J Cyst Fibros 14 (2015), 714–719.
16. 16 Salinas, D.B., Sosnay, P.R., Azen, C., Young, S., Raraigh, K.S., Keens, T.G., et al. Benign and deleterious cystic fibrosis transmembrane conductance regulator mutations identified by sequencing in positive cystic fibrosis newborn screen children from California. PLoS ONE, 11, 2016, e0155624.
17. 17 Carlson, D., McKeen, E., Mitchell, M., Torres, B., Parad, R., Comeau, A.M., et al. Oropharyngeal flora in healthy infants: observations and implications for cystic fibrosis care. Pediatr Pulmonol 44 (2009), 497–502.
18. 18 Rosenfeld, M., Bernardo-Ocampo, C., Emerson, J., Genatossio, A., Burns, J., Gibson, R., Prevalence of cystic fibrosis pathogens in the oropharynx of healthy children and implications for cystic fibrosis care. J Cyst Fibros 11 (2012), 456–457.